The landscape of regulatory submissions has undergone a significant transformation over the past decade, driven by technological advancements and the need for more efficient regulatory processes. This blog post will explore the key changes that have shaped the way industry and regulatory bodies interact and manage drug and biological product applications.

The Evolution

Early 2010s: Document-Based Submissions

  • Regulatory submissions were primarily document-based.
  • Manual and technical efforts were substantial due to diverse document formats.
  • Electronic submissions were being introduced but were not yet the standard.

Mid-2010s: Move Towards Electronic Submissions (e-Submissions)

  • The FDA and other regulatory bodies began to encourage or mandate electronic submissions.
  • The International Council for Harmonisation (ICH) worked on standardizing the Common Technical Document (e-CTD) format.
  • Initiatives like the FDA's Electronic Submissions Gateway (ESG) became more prominent.

Late 2010s: Standardization and Global Initiatives

  • The FDA released guidance on electronic submissions for postmarketing safety reports and other regulatory requirements.
  • The ICH e-CTD format became mandatory in various regions, including for new drug and biologic product registrations.
  • Projects like the OpERA programme by the Centre for Innovation in Regulatory Science (CIRS) aimed to measure process and performance in regulatory agencies.

Early 2020s: Advanced Technologies and Real-World Data

  • The use of big data and real-world evidence (RWE) began to influence regulatory decision-making.
  • The FDA's Sentinel Initiative and the European DARWIN EU network were examples of using large datasets for monitoring product safety.
  • The 21st Century Cures Act in the US and similar initiatives globally aimed to modernize regulatory frameworks to accommodate new technologies and therapies.

Mid-2020s: Emphasis on Efficiency and Global Harmonization

  • Efforts to reduce review cycles and approval times for drug applications intensified.
  • Regulatory agencies focused on risk-based evaluations to effectively use resources.
  • International coordination efforts, such as Project Orbis and the Access Consortium, facilitated faster and more synchronized global drug approvals.

Late 2020s: Digital Transformation and Pandemic Response

  • The COVID-19 pandemic accelerated the adoption of digital tools and processes for regulatory submissions.
  • Regulatory agencies adapted quickly to evaluate vaccines and treatments, emphasizing the need for rapid and flexible evaluation methods.
  • The pandemic underscored the importance of having strong, adaptable regulatory systems capable of responding to public health emergencies.

The Shift to Electronic Submissions

One of the most notable changes in the regulatory submission process is the widespread adoption of electronic submissions (e-submissions). The move away from paper-based submissions has been supported by regulations and guidance documents that promote or require the use of data standards in electronic regulatory submissions. This transition has been facilitated by the implementation of standardized electronic formats, such as the International Council for Harmonisation's (ICH) Electronic Common Technical Document (e-CTD).

Standardization and International Harmonization

The push for standardization has been a global effort, with various projects undertaken by organizations like the ICH. These efforts aim to create a unified set of documents and data submission formats, reducing the manual and technical efforts previously required. However, it's important to note that not all standardization work includes European involvement, indicating a need for continued international collaboration.

Legislative and Regulatory Milestones

Several legislative acts and final rules have been instrumental in advancing the electronic submission process. Key among these are:

  • The Food and Drug Administration Amendments Act (FDAAA) of 2007, which required electronic drug establishment registration and drug listing information in a standardized format.
  • The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, which mandated that submissions be provided in an electronic format specified by the FDA.
  • The 21st Century Cures Act of 2016, which aimed to modernize clinical trial designs and accelerate the drug development process.

Enhanced Review Tools and Systems

The FDA has introduced electronic review tools and systems to improve the review process. These tools are designed to handle the standardized data more effectively, allowing for a more streamlined review process that can lead to faster decision-making.

Public Involvement and Transparency

Regulatory authorities have also made efforts to increase transparency and public involvement. For example, the FDA allows for the submission of comments on any guidance at any time, providing stakeholders with the opportunity to influence regulatory practices.

Challenges and Ongoing Efforts

Despite these advancements, the industry still faces challenges in ensuring that the promised timelines for drug and biologic registration are met. Regulatory bodies continue to work on refining the e-submission process, ensuring system sustainability, and expanding electronic processes to all types of submissions.

Conclusion

The past decade has seen a significant shift towards electronic regulatory submissions, driven by the need for efficiency and supported by legislative and regulatory changes. While there have been substantial improvements, the journey towards a fully optimized and harmonized global regulatory submission process continues. The industry and regulatory bodies alike must remain adaptable and collaborative to meet the evolving demands of healthcare regulation in the digital age. A regulatory partner like Freyr emerges as a key player, offering comprehensive capabilities to support companies in navigating the complex landscape of regulatory submissions. With expertise in electronic submissions, regulatory compliance, and global harmonization, our team of experts enable organizations to streamline their regulatory processes and ensure compliance with evolving requirements.

Author: Sonal Gadekar

Subscribe to Freyr Blog